Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/38664
Title: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Authors: 
Keywords: 
Mesh: 
Issue Date: Jan-2018
Citation: Clin Transl Oncol.2018 Jan;(20)1:57-68
Abstract: Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
PMID: 29134562
URI: https://hdl.handle.net/20.500.12530/38664
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5785604.pdf439.91 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.